2 October 2015

The Institute of Pharmacology of Sherbrooke (IPS) and the Centre for Drug Research and Development (CDRD) have unveiled a project in which they have joined forces to accelerate the development of a new therapy for treating prostate cancer.

The specific goal of the partnership is to create an oral formulation—as opposed to the more invasive injection—for C23, an inhibitor of the PACE4 enzyme, which is associated with this type of cancer.

Preliminary studies by Dr. Robert Day, research professor at the Université de Sherbrooke and the Centre de recherche du CHUS (CRCHUS – Research Centre), have shown that the inhibitor slows the growth of prostate cancer tumours.

Pr Jean-Pierre Perreault, Pr Robert Day, Dr Sam White, and Pr Éric Marsault

Dr. Day and his team will therefore pursue their research in this regard. For its part, the CDRD will assess the safety aspect and the risk of side effects and may conduct more advanced chemical studies to resolve any potential problems.

This collaboration was announced during the second Sherbrooke International Life Sciences Summit (SILS) and is part of the recent association of these two organizations, in June 2015, to create the Sherbrooke-ACCESS-CDRD drug development node.

Sources: Université de Sherbrooke and CDRD
Photo credit: Robert Dumont

———————————–

RELATED ARTICLES

» Drug Development Hub in Sherbrooke